Bausch health hives off Bausch + Lomb, news pushes stock prices up

Bausch Health's shares surged on news of the separation of its healthcare and eyecare companies.



PUBLISHED BY
Anna Domanska



TAGS:


12 months ago




Canada-headquartered Bausch Health Companies Inc plans to hive off its eye-care unit, Bausch + Lomb, into a separate publicly listed company. It acquired the eyewear company for $9 billion in 2013.

The spinoff will establish two separate companies that include:

A fully integrated, pure-play eye-health company built on the iconic Bausch + Lomb brand and long history of innovation; it brought in revenue of about $3.7 billion in 2019.

A diversified pharmaceutical company with leading positions in gastroenterology, aesthetics/dermatology, neurology, and international pharmaceuticals. It brought in a revenue of about $4.9 billion in 2019.

Bausch Health Eyewear Spinoff Bausch + Lomb

The news of spin off has pushed Bausch’s U.S. shares up 28% before the opening bell.

The news has pushed Bausch’s U.S. shares up 28% before the opening bell.

The move follows a spate of investigations that Bausch Health is facing for its accounting practices under its previous management. It was earlier known as Valeant Pharmaceuticals. Three of its ex-executives have been fined and settled charges of misleading disclosures to the US regulatory authorities. The company has also agreed to pay $45 million as fine.

Bausch + Lomb has been the one bright spot for the company since it was acquired in 2013 and had brought in a stable income and revenue.

The charges of inappropriate accounting led to Bausch suffering a huge fall in its share prices. Bausch also has a huge debt burden, which compounded the problem.

“We are committed to taking action to unlock what we see as unrecognized value in Bausch Health shares, and we believe that separating our business into two highly focused, stand-alone companies is the way to accomplish that goal,” said Joseph C. Papa, chairman, and CEO of Bausch Health.

“Four years ago, we initiated a multi-phase plan, first to stabilize and then to transform Bausch Health into a company positioned to deliver long-term organic growth. We have divested approximately $4 billion of non-core assets, paid down over $8 billion of debt, resolved numerous legacy legal issues and managed a loss of exclusivity on an approximately $1.4 billion product portfolio, while also investing in R&D, new product launches­­ and core franchises with attractive growth opportunities.”

“Our Board of Directors and management team have been working on alternatives over the last 12 months to determine how to best unlock value across our businesses, and we believe that the time is right to begin the separation process, so each business has greater flexibility to pursue strategic opportunities in their respective markets.”

The group also unveiled second-quarter earnings that included a loss of 92 cents per share on weaker-than-expected revenue of $1.66 billion. The coronavirus seems to have had an effect on eye care sales too.

Bausch Health also brought down its full-year adjusted earnings guidance to a range of $3.15 to $3.30 per share, and revenue in the range of $7.8 billion to $8 billion.

Bausch’s U.S. shares, which touched a record high of $263 in 2015, were trading at $24.85.

Bausch Health’s management has started looking out for executive leadership teams to head each company. The company says that as the separation process starts, it will provide additional information on the future management teams and Boards of Directors for both companies.

Anna Domanska
Anna Domanska is an Industry Leaders Magazine author possessing wide-range of knowledge for Business News. She is an avid reader and writer of Business and CEO Magazines and a rigorous follower of Business Leaders.

Recent Posts

PepsiCo relinquishes control of Tropicana for $3.3 billion

PepsiCo relinquishes control of Tropicana for $3.3 billion

PepsiCo will sell Tropicana and other juice brands to a private equity firm in exchange for pre-tax proceeds of 3.3 billion dollars.
17 hours ago
Sanofi bets big on mRNA future with Translate Bio acquisition offer

Sanofi bets big on mRNA future with Translate Bio acquisition offer

Sanofi’s CEO Paul Hudson is dead serious about mRNA technology and capabilities with a $3.2 billion acquisition offer to Translate Bio.
19 hours ago
Top 6 Energy Dividend Stocks to include in your portfolio

Top 6 Energy Dividend Stocks to include in your portfolio

The entire energy sector yield hovers around 4%, according to the Energy Select Sector SPDR exchange-traded fund.
1 day ago
Monte dei Paschi performance below par in EU banks stress test

Monte dei Paschi performance below par in EU banks stress test

The depletion of capital at each bank under the test’s harshest scenario will be closely scrutinised, and could potentially lead to hostile takeovers
3 days ago
Nokia to launch T20 tablet with 10.36 inch display

Nokia to launch T20 tablet with 10.36 inch display

The Nokia T20 will sport a 10.36-inch display and will have 4 GB RAM along with 64 gigs of native storage.
5 days ago
Ford sees surprise Q2 profit despite chip shortage and manufacturing hassles

Ford sees surprise Q2 profit despite chip shortage and manufacturing hassles

“The business is ‘spring loaded’ for a rebound when semiconductor supplies stabilize and more closely match demand.”
5 days ago